IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Osiris Therapeutics, Inc. (“Osiris” or the “Company”) (NASDAQ: OSIR). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
If you purchased shares of Osiris during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by email at firstname.lastname@example.org.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
The investigation concerns whether the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Specifically, the investigation will focus on the Company’s announcement that it has determined to correct the revenue recognition for three contracts which will result in a decrease in product revenues of $1.8 million in the first quarter of 2015, a decrease in product revenue of $1.0 million in the second quarter, an increase in product revenues of $0.8 million in the third quarter of 2015 and a decrease in product revenues of $1.1 million in 2014.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by email at email@example.com.
This press release may constitute Attorney Advertising in some jurisdictions.